Abstract:Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion and the exposure of infiltrating CAR T-cells to a panoply of immune suppressive checkpoint molecules, cytokines, and metabolic stresses that are not conducive to efficient immune reactions and can thereby render these cells anergic, exhausted, or apoptotic. This mini-review summarizes these hurdles and describes some recent approaches and innovations to genetically re-engineer CAR T-cells to counter inhibitory influences found in the tumor microenvironment. Novel immunotherapy drug combinations to potentiate the activity of CAR T-cells are also discussed. As our understanding of the immune landscape of tumors improves and our repertoire of immunotherapeutic drugs expands, it is envisaged that the efficacy of CAR T-cells against solid tumors might be potentiated using combination therapies, which it is hoped may lead to meaningful improvements in clinical outcome for patients with refractory solid malignancies.

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

New Chimeric Antigen Receptor Design for Solid Tumors

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Current Progress in Chimeric Antigen Receptor T‐cell Therapy for Malignant Tumors

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Research Advances in Chimeric Antigen Receptor-Modified T-cell Therapy (Review)

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

A long way to the battlefront: CAR T cell therapy against solid cancers.